In this activity, several experts discuss appropriate definitions of different types of CINV and theories behind its development, and offer instructive commentary on evaluating patient and chemotherapy-related risk factors for emesis in oncology settings. In addition, the faculty describe strategies for preventing CINV according to risk level, as well as optimal agent selection and dosing.

Upon completion of this activity, participants will be able to:

• Differentiate between the various types of chemotherapy-induced nausea and vomiting (CINV), including anticipatory, acute-onset, and delayed-onset nausea/vomiting
• Perform an assessment of patients at risk for CINV and identify factors affecting the selection of management strategies, such as age, gender, and history of nausea/vomiting
• Test physician assumptions on the appropriate use of therapies for the management of CINV, including proper timing, dosing, and administration of agents such as 5-HT3 receptor antagonists, steroid approaches, and NK1-receptor antagonists, among others
• Demonstrate knowledge of recently published or presented efficacy findings on the potential role of modern antiemetic agents across the broad range of chemotherapy regimens associated with low, moderate, and high emetic risk

This activity has been designed to meet the educational needs of oncologists, advanced practice oncology nurses and physician assistants, and other clinicians involved in managing CINV in oncology settings.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media:

Internet

Release and Expiration Dates:

December 17, 2009 - December 16, 2010

Time to Complete:

45 minutes

Hans-Joachim Schmoll, MD, PhD
Professor of Medicine
Head Department of Oncology and Hematology
Associate Professor of Internal Medicine, and Hematology/ Oncology, Hemostaseology
University Clinic Halle (Saale)
Oncology / Hematology / Hemostaseology
Martin Luther University
Halle, Germany

Hans-Joachim Schmoll, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Honoraria from F. Hoffmann-La Roche Ltd; Merck Sharp & Dohme Ltd.; and sanofi-aventis.
Advisory Board for F. Hoffmann-La Roche Ltd; Merck Sharp & Dohme Ltd.; and sanofi-aventis.
Other Financial or Material Support from Editorial Board involvement with Onkologie (International Journal for Cancer Research and Treatment).

Richard J. Gralla, MD
Chief of Hematology-Oncology
Vice President for Cancer Services
Monter Cancer Center at the North Shore LIJ Health System
Lake Success, New York

Richard J. Gralla, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Eisai Inc.; GlaxoSmithKline; and Merck & Co., Inc.
Grant/Research Support from Helsinn Healthcare S.A.
Honoraria from Helsinn Healthcare S.A. and Merck & Co., Inc.

Mark G. Kris, MD
Chief, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York

Mark G. Kris, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for GlaxoSmithKline and Merck & Co., Inc.
Honorarium from sanofi-aventis.

Carmine DeLuca
PVI, PeerView Institute for Medical Education, Inc.

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University School of Pharmacy staff have no relationships to disclose.

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University School of Pharmacy designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education is approved as a provider of continuing nursing education by the Indiana State Nurses Association. ISNA is accredited as an approver of continuing education in nursing by the Commission on Accreditation of the American Nurses Credentialing Center. Code #CNEP09-22.

This program has been approved for 0.75 contact hour(s).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

Pharmacists

Purdue University School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Program Number (UPN): 0018-999-09-241-H01-P, 0.75 contact hours (0.75 CEUs).

This activity is supported by an educational grant from